ESH ALL 2021 | Unanswered questions in Ph+ ALL
Yves Chalandon, MD, PhD, University of Geneva, Geneva, Switzerland, outlines the biggest unanswered questions in the field of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) and well as where the research focus should be in the coming years. Prof. Chalandon highlights the necessity of considering the risk of relapse, risk of mutation and resistance and discusses chemotherapy-free regimens for Ph+ ALL and the use of blinatumomab after transplant. This interview took place during the 2021 European School of Hematology (ESH) 2nd Translational Research Conference on Acute Lymphoblastic Leukemia.
Disclosures
Speaker’s Bureau: Incite
Scientific Advisory Board: Incite, BMS, Pfizer, Abbvie, MSD, Roche, Novartis, Amgen
Other: Incite, BMS, Pfizer, Abbvie, MSD, Roche, Novartis, Gilead, Amgen, Jazz, AstraZeneca
